Anteris Technologies Global Corp - Asset Resilience Ratio

Latest as of December 2024: 33.27%

Anteris Technologies Global Corp (AVR) has an Asset Resilience Ratio of 33.27% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$43.38 Million
≈ $30.69 Million USD Cash + Short-term Investments

Total Assets

AU$130.39 Million
≈ $92.26 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Anteris Technologies Global Corp's Asset Resilience Ratio has changed over time. Check Anteris Technologies Global Corp PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Anteris Technologies Global Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Anteris Technologies Global Corp stock valuation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$43.38 Million 33.27%
Total Liquid Assets AU$43.38 Million 33.27%

Asset Resilience Insights

  • Very High Liquidity: Anteris Technologies Global Corp maintains exceptional liquid asset reserves at 33.27% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Anteris Technologies Global Corp Industry Peers by Asset Resilience Ratio

Compare Anteris Technologies Global Corp's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Edwards Lifesciences Corp
NYSE:EW
Medical Devices 9.20%
DexCom Inc
NASDAQ:DXCM
Medical Devices 19.55%
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
Medical Devices 19.31%
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
Medical Devices 6.09%
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
Medical Devices 10.88%
Theradiag SA
PA:ALTHE
Medical Devices 15.59%
Corentec Co Ltd
KQ:104540
Medical Devices 2.80%
Adherium Ltd
AU:ADR
Medical Devices 15.45%

Annual Asset Resilience Ratio for Anteris Technologies Global Corp (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Anteris Technologies Global Corp.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 33.27% AU$43.38 Million
≈ $30.69 Million
AU$130.39 Million
≈ $92.26 Million
+32.89pp
2022-12-31 0.38% AU$88.76K
≈ $62.80K
AU$23.48 Million
≈ $16.61 Million
+0.08pp
2021-12-31 0.30% AU$88.56K
≈ $62.66K
AU$29.48 Million
≈ $20.86 Million
-0.58pp
2020-12-31 0.88% AU$111.00K
≈ $78.54K
AU$12.65 Million
≈ $8.95 Million
-26.57pp
2019-12-31 27.44% AU$7.14 Million
≈ $5.05 Million
AU$26.00 Million
≈ $18.40 Million
+10.46pp
2018-12-31 16.99% AU$5.41 Million
≈ $3.83 Million
AU$31.86 Million
≈ $22.54 Million
-1.02pp
2017-12-31 18.01% AU$5.11 Million
≈ $3.61 Million
AU$28.37 Million
≈ $20.07 Million
--
2016-12-31 0.00% AU$0.00
≈ $0.00
AU$28.58 Million
≈ $20.22 Million
--
2015-12-31 0.00% AU$0.00
≈ $0.00
AU$26.78 Million
≈ $18.95 Million
--
2010-12-31 1.98% AU$291.36K
≈ $206.16K
AU$14.75 Million
≈ $10.44 Million
--
pp = percentage points

About Anteris Technologies Global Corp

AU:AVR Australia Medical Devices
Market Cap
$773.67 Million
AU$1.09 Billion AUD
Market Cap Rank
#9883 Global
#256 in Australia
Share Price
AU$11.29
Change (1 day)
+0.00%
52-Week Range
AU$5.05 - AU$15.30
All Time High
AU$83.50
About

Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calci… Read more